| |
Transform the Industry with Your Innovation! Submissions are now open for the Fierce Life Sciences Innovation Awards. Click to submit your entry and learn more about the categories and criteria.
|
|
Today’s Big NewsAug 15, 2024 |
|
Tuesday, August 27, 2024 | 12pm ET / 9am PT Join us for a one-hour, comprehensive discussion on the importance of leveraging federated AI for innovative data collection in real-world research. Register now.
|
|
| By Kevin Dunleavy,Fraiser Kansteiner The White House has revealed significantly reduced prices for 10 prescription drugs affected by the first wave of Medicare negotiations mandated by the Inflation Reduction Act, the Biden administration initiative which includes several measures designed to lower the cost of healthcare in the U.S. |
|
|
|
By Conor Hale Using sensors developed by Blackrock Neurotech and AI text-to-speech software that sounds like his own voice, 45-year-old Casey Harrell was able to say, “It feels a lot like me." |
By James Waldron Turnstone Biologics is narrowing the focus of phase 1 trials of its lead tumor-infiltrating lymphocyte, with cutaneous melanoma and breast cancer no longer in the mix. |
By Kevin Dunleavy Less than three months after a Delaware federal jury ordered AstraZeneca to pay $107.5 million to Pfizer in a patent infringement case, a Delaware judge has nullified the award and invalidated the patents behind the original lawsuit. |
|
September 9-12, 2024 | Philadelphia, PA Join us at Digital Pharma East, the leading event for digital innovation in the pharmaceutical industry. Dive into key topics including Digital Marketing, Data & Analytics, and Patient Engagement. Learn from industry experts, network with peers, and explore cutting-edge strategies to drive your digital initiatives forward. Last Chance – one month left!
|
|
By Angus Liu To Juergen Eckhardt, M.D., who leads both the investment arm Leaps by Bayer and the pharma business development team, the ongoing overhaul won’t disrupt the German company’s dealmaking appetite. |
By Zoey Becker Despite missing the trial's primary endpoint of time to lesion resolution, the study suggested that the treatment may be most beneficial for those treated early and those with severe disease. |
By Angus Liu Incyte has expanded its graft-versus-host disease offerings beyond Jakafi. The new addition comes from Syndax Pharma-partnered axatilimab, which received FDA approval as a third-line therapy. |
By Darren Incorvaia Céline Dion stands alone as a singer, a chart-topping ballad-belter who recorded some of the most iconic songs of all time, including “My Heart Will Go On” from the "Titanic" soundtrack. But, in 2022, Dion made headlines not for her one-in-a-million voice, but for a one-in-a-million diagnosis: a rare neurological disease called stiff-person syndrome. |
By Fraiser Kansteiner Roughly one year since the commercial rollout of Tarsus Pharmaceuticals’ first marketed product Xdemvy, the company is touting the medicine’s debut as “one of the most successful eye care launches to date.” |
By Conor Hale The Edison system uses vibrations from sound waves to create bubbles of gas within a tumor, with enough energy to destroy the targeted tissue. |
By Gabrielle Masson After Arrowhead cleared out work on a clinical-stage cardiovascular candidate, the company is filling the blank space with two obesity assets, both slated to enter the clinic in early 2025. |
By James Waldron Two and half years after it signed a $100 million biobucks deal with Aarvik Therapeutics to work on an undisclosed “novel oncology drug,” ArriVent BioPharma has decided to license the candidate—and confirmed that it’s an antibody-drug conjugate. |
Fierce podcastsDon’t miss an episode |
| | In this week's episode of "Podnosis," we’re discussing the challenges and opportunities for telehealth, given some notable setbacks for the industry in recent months. |
|
|---|
|
|
|
Thursday, September 12, 2024 | 10am ET / 7am PT Nitrosamines, potent carcinogens, have prompted stringent regulations for their detection and control in various products. With regulatory bodies demanding robust analytical methods and risk assessments, pharmaceutical and medical devices manufacturers must stay on top of the current regulatory landscape and compliance strategies. Register now for access to the key insights you need to know. |
|
| WhitepaperThis paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
